Franco Valle
Directeur Financier/CFO chez BIOMEA FUSION, INC.
Fortune : 267 435 $ au 30/04/2024
Profil
Franco Valle's current job is as the Chief Financial & Accounting Officer at Biomea Fusion, Inc. Mr. Valle's former jobs include being a Senior Director-Accounting at Pharmacyclics LLC, a Controller at Iovance Biotherapeutics, Inc. from 2017 to 2018, a Principal Accounting Officer & SVP-Finance at Eidos Therapeutics, Inc. from 2020 to 2021, and a Senior Vice President-Finance at Graphite Bio, Inc. Mr. Valle also worked as a Senior Accounting Officer at Pharmacyclics, Inc. from 2012 to 2015.
Mr. Valle obtained his undergraduate degree from San Jose State University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
BIOMEA FUSION INC
0,07% | 31/03/2024 | 25 543 ( 0,07% ) | 267 435 $ | 30/04/2024 |
Postes actifs de Franco Valle
| Sociétés | Poste | Début |
|---|---|---|
| BIOMEA FUSION, INC. | Directeur Financier/CFO | 26/07/2021 |
Anciens postes connus de Franco Valle
| Sociétés | Poste | Fin |
|---|---|---|
| EIDOS THERAPEUTICS, INC. | Directeur Financier/CFO | 01/04/2021 |
| IOVANCE BIOTHERAPEUTICS, INC. | Directeur Financier/CFO | 14/08/2017 |
Pharmacyclics, Inc.
 Pharmacyclics, Inc. Pharmaceuticals: MajorHealth Technology Pharmacyclics, Inc. develops drugs to treat cancer. The private company is based in Sunnyvale, CA. Robert William Duggan has been the CEO of the company since 2015. | Comptroller/Controller/Auditor | 01/05/2015 |
| PHARMACYCLICS, INC. | Comptroller/Controller/Auditor | - |
| LENZ THERAPEUTICS, INC. | Directeur Financier/CFO | - |
Formation de Franco Valle
| San Jose State University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Eidos Therapeutics, Inc.
 Eidos Therapeutics, Inc. BiotechnologyHealth Technology Eidos Therapeutics, Inc. focuses on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). Its product include the AG10, an orally-administered small molecule designed to potently stabilize TTR, suggesting a treatment with the potential to halt the progression of ATTR. The company was founded by Graef Isabella and Alhamadsheh Mamoun on August 6, 2013 and is headquartered in San Francisco, CA. | Health Technology |
| Biomea Fusion, Inc. | |
Graphite Bio, Inc.
 Graphite Bio, Inc. BiotechnologyHealth Technology Graphite Bio, Inc. is a clinical-stage gene editing company. It engages in the business of developing therapies that harness targeted gene integration to treat or cure serious diseases. The company was founded by Matthew Porteus and Maria Grazia Roncarolo on June 1, 2017 and is headquartered in South San Francisco, CA. | Health Technology |
Pharmacyclics LLC
 Pharmacyclics LLC Pharmaceuticals: MajorHealth Technology Pharmacyclics LLC engages in developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. It has product candidates in clinical development and several preclinical molecules in optimization. The company was founded by Jonathan Sessler and Richard Miller in 1991 and is headquartered in Sunnyvale, CA. | Health Technology |
Pharmacyclics, Inc.
Pharmacyclics, Inc. Pharmaceuticals: MajorHealth Technology Pharmacyclics, Inc. develops drugs to treat cancer. The private company is based in Sunnyvale, CA. Robert William Duggan has been the CEO of the company since 2015. | Health Technology |
